c-Met Signaling as a Therapeutic Target in Head and Neck Cancer

被引：11

作者：

Centuori, Sara M. ^{[1
,2
]}

Bauman, Julie E. ^{[3
,4
]}

机构：

[1] Univ Arizona, Coll Med, Dept Med, Tucson, AZ USA

[2] Univ Arizona, Canc Ctr, Tucson, AZ USA

[3] George Washington Univ, Dept Med, Sch Med & Hlth Sci, Washington, DC USA

[4] George Washington Univ, George Washington Canc Ctr, Washington, DC USA

来源：

CANCER JOURNAL | 2022年 / 28卷 / 05期

关键词：

c-Met; head and neck squamous cell carcinoma; HGF; HEPATOCYTE GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; PHASE-II TRIAL; CAR-T-CELLS; TUMOR-ASSOCIATED FIBROBLASTS; LUNG-CANCER; TYROSINE KINASE; SCATTER FACTOR; DENDRITIC CELLS; FACTOR-RECEPTOR;

D O I：

10.1097/PPO.0000000000000619

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite a dearth of activating driver mutations in head and neck squamous cell carcinoma (HNSCC), aberrant activation of the oncogenes, epidermal growth factor receptor (EGFR), and c-Met is near-universal in human papillomavirus (HPV)-negative disease. Although EGFR activation drove the successful development of the anti-EGFR monoclonal antibody cetuximab in HNSCC, no c-Met-targeting therapy has gained regulatory approval. Inhibition of the c-Met pathway may subvert oncogenesis within the tumor-intrinsic compartment, blocking tumoral proliferation, invasion, migration, and metastasis, or the tumor-extrinsic compartment, modulating the immunosuppressive tumor microenvironment. This review discusses the rationale and current drug development strategies for targeting c-Met or its exclusive ligand hepatocyte growth factor (HGF) in HNSCC.

引用

页码：346 / 353

页数：8

共 95 条

[1] Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx [J].

Aebersold, DM ;

Landt, O ;

Berthou, S ;

Gruber, G ;

Beer, KT ;

Greiner, RH ;

Zimmer, Y .

ONCOGENE, 2003, 22 (52) :8519-8523

[2] Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 [J].

Agrawal, Nishant ;

Frederick, Mitchell J. ;

Pickering, Curtis R. ;

Bettegowda, Chetan ;

Chang, Kyle ;

Li, Ryan J. ;

Fakhry, Carole ;

Xie, Tong-Xin ;

Zhang, Jiexin ;

Wang, Jing ;

Zhang, Nianxiang ;

El-Naggar, Adel K. ;

Jasser, Samar A. ;

Weinstein, John N. ;

Trevino, Lisa ;

Drummond, Jennifer A. ;

Muzny, Donna M. ;

Wu, Yuanqing ;

Wood, Laura D. ;

Hruban, Ralph H. ;

Westra, William H. ;

Koch, Wayne M. ;

Califano, Joseph A. ;

Gibbs, Richard A. ;

Sidransky, David ;

Vogelstein, Bert ;

Velculescu, Victor E. ;

Papadopoulos, Nickolas ;

Wheeler, David A. ;

Kinzler, Kenneth W. ;

Myers, Jeffrey N. .

SCIENCE, 2011, 333 (6046) :1154-1157

[3] Activated HGF-c-Met Axis in Head and Neck Cancer [J].

Arnold, Levi ;

Enders, Jonathan ;

Thomas, Sufi Mary .

CANCERS, 2017, 9 (12)

[4] The HGF Receptor/Met Tyrosine Kinase Is a Key Regulator of Dendritic Cell Migration in Skin Immunity [J].

Baek, Jea-Hyun ;

Birchmeier, Carmen ;

Zenke, Martin ;

Hieronymus, Thomas .

JOURNAL OF IMMUNOLOGY, 2012, 189 (04) :1699-1707

[5] Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression [J].

Balan, Murugabaskar ;

Mier y Teran, Eduardo ;

Waaga-Gasser, Ana Maria ;

Gasser, Martin ;

Choueiri, Toni K. ;

Freeman, Gordon ;

Pal, Soumitro .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (13) :8110-8120

[6] c-Met Expression Is a Marker of Poor Prognosis in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Treated With Chemoradiation [J].

Baschnagel, Andrew M. ;

Williams, Lindsay ;

Hanna, Alaa ;

Chen, Peter Y. ;

Krauss, Daniel J. ;

Pruetz, Barbara L. ;

Akervall, Jan ;

Wilson, George D. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (03) :701-707

[7] Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity [J].

Basu, D. ;

Nguyen, T-T K. ;

Montone, K. T. ;

Zhang, G. ;

Wang, L-P ;

Diehl, J. A. ;

Rustgi, A. K. ;

Lee, J. T. ;

Weinstein, G. S. ;

Herlyn, M. .

ONCOGENE, 2010, 29 (29) :4170-4182

[8] Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC). [J].

Bauman, Julie E. ;

Saba, Nabil F. ;

Roe, Denise ;

Bauman, Jessica R. ;

Kaczmar, John M. ;

Bhatia, Aarti K. ;

Muzaffar, Jameel ;

Julian, Ricklie Ann ;

Wang, Steven ;

Bearelly, Shethal ;

Baker, Audrey ;

Steuer, Conor Ernst ;

Giri, Anshu ;

Burtness, Barbara ;

Centuori, Sara ;

Caulin, Carlos ;

Saboda, Kathylynn ;

Obara, Stefanie ;

Chung, Christine H. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[9] Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer [J].

Bauman, Julie E. ;

Ohr, James ;

Gooding, William E. ;

Ferris, Robert L. ;

Duvvuri, Umamaheswar ;

Kim, Seungwon ;

Johnson, Jonas T. ;

Soloff, Adam C. ;

Wallweber, Gerald ;

Winslow, John ;

Gaither-Davis, Autumn ;

Grandis, Jennifer R. ;

Stabile, Laura P. .

CANCERS, 2020, 12 (06) :1-17

[10] Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells [J].

Benkhoucha, Mahdia ;

Santiago-Raber, Marie-Laure ;

Schneiter, Gregory ;

Chofflon, Michel ;

Funakoshi, Hiroshi ;

Nakamura, Toshikazu ;

Lalive, Patrice H. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (14) :6424-6429

← 1 2 3 4 5 6 7 8 9 10 →